InsideScientific | A Scientist.com Company’s Post

In the interview with Clinical Trial Vanguard, our CEO Ping Cao discusses targeting “hard to drug” proteins that evade traditional small-molecule therapies due to their complex structures and functions BridGene, leveraging its proprietary IMTAC™ technology, seeks to innovate drug discovery by focusing on proteins essential in disease pathways yet difficult to target. This approach aims to pioneer new classes of medicines that can directly interact with and modulate protein functions, addressing significant unmet medical needs in areas like oncology and neurodegenerative diseases. Read more here: https://lnkd.in/dSHR5UU3 #DrugDiscovery #Biotechnology #ClinicalTrials #BridGeneBiosciences #IMTACPlatform #Oncology #NeurodegenerativeDiseases #InnovativeTherapies #HardToDrugProteins #PharmaceuticalResearch #MolecularBiology #ProteinTargeting #PrecisionMedicine #BioTechInnovation #MedicalResearch #CancerResearch

Organizations Who are Conducting Human Trials with iPSC-Derived Cellular Therapeutics - https://lnkd.in/gE3uiwby Despite their enormous promise though, no iPSC-derived cellular therapeutic has yet to receive regulatory approval in any jurisdiction worldwide. With this said, at least a dozen different entities are actively testing iPSC-derived cellular products in human trials. There are also at least 62 different companies that are developing iPSC-derived cellular therapeutics within preclinical and clinical testing environments. Learn more here: https://lnkd.in/gE3uiwby #ipscells #stemcells #celltherapies Cynata Therapeutics Fate Therapeutics Inc. Osaka University Kyoto University Masonic Cancer Center, University of Minnesota Keio University Tehran University of Medical Sciences The National Institutes of Health

ICYMI, very grateful to Monash Partners Comprehensive Cancer Consortium for the opportunity to showcase our SomaLogic's novel next gen proteomics solutions. Please join us tomorrow for a lunchtime seminar and explore the latest proteomics advancement in oncology. More details in the post below 👇 #precisionmedicine #proteomics #clinicaltrials #cancer #oncology

🔬 Discover novel biomarkers using KinomePro technology from PamGene International B.V. 🔬 🌟 Disease Classification Determine disease phenotypes, stages, and patient subgroups based on kinase activity signatures. 🌟 Prognostic Biomarkers Develop biomarkers to assess disease progression or risk of recurrence by correlating patient kinase activity profiles with clinical outcomes. 🌟 Therapy Response Prediction Identify patient subpopulations most likely to respond to standard of care or novel therapies using active kinase profiling in patient biopsies or surrogate cells. 🌟 Pharmacodynamic Biomarkers Discover molecular indicators of drug effects and elucidate pathways impacted by treatment using kinase activity profiles in patient-derived tissues. 💡 Harness the power of KinomePro to gain insights into discriminative drug responses, analyzing and optimizing kinase inhibitors and discovery of novel biomarkers, targets and pathways. ➡️ Contact us for details at sales@thesciencesupport.com. #clinical #research #biomarkers #biopsy #cancer #treatment #diagnostics #pharma #biotech

Exploring the Booming $42.0 Billion Cancer Biomarkers Market 𝗗𝗼𝘄𝗻𝗹𝗼𝗮𝗱 𝗣𝗗𝗙 𝗕𝗿𝗼𝗰𝗵𝘂𝗿𝗲: https://lnkd.in/d2AzRpZZ The size of global #cancerbiomarkers market in terms of revenue was estimated to be worth $24.5 billion in 2024 and is poised to reach $42.0 billion by 2029, growing at a CAGR of 11.3% from 2024 to 2029. BioAgilytix Bill & Melinda Gates Medical Research Institute Owkin Quanterix Scipher Medicine Metabolon, Inc. Kura Oncology, Inc. InsideTracker Advanced Cell Diagnostics Biodesix, Inc. Eurofins Central Laboratory Koneksa Biocare Medical Clinical ink Denali Therapeutics Biofourmis KCAS Bio Exosome Diagnostics Drug Discovery News Biological Dynamics Nucleai BostonGene AbleTo Inc. MESO SCALE DIAGNOSTICS, LLC. Alto Neuroscience Mitsubishi Tanabe Pharma America AiCure Paige Amador Bioscience Geneoscopy CorDx HALO Precision Diagnostics Aster Insights RareCyte, Inc. Sanguine HiFiBiO Therapeutics Active Motif InterVenn Biosciences Ethos Laboratories Flagship Biosciences, Inc.

Today at the #AACR 2024 conference, we presented new preclinical data on our highly selective oral SMARCA2 degrader (PRT7732), our potentially best-in-class CDK9 inhibitor (PRT2527), and our next-generation oral CDK4/6 inhibitor (PRT3645). Read the press release and review the posters here: https://lnkd.in/ei2QjDer “These presentations demonstrate our core competencies in medicinal chemistry and cancer biology to optimize and deliver compounds to the clinic with the potential to succeed as differentiated first- and/or best-in-class new therapies,” said Andrew Combs, Ph.D., Chief Chemistry Officer at Prelude Therapeutics. Peggy Scherle, Ph.D., Chief Scientific Officer at Prelude, stated, “Advancement of our second highly selective SMARCA2 degrader strengthens Prelude’s leadership position in the emerging use of SMARCA2 protein degradation as a potential treatment option for underserved patients with cancer. With both a first-in-class IV SMARCA2 degrader, PRT3789, in Phase 1 clinical development and now our oral SMARCA2 degrader, PRT7732, expected to enter the clinic later this year, we believe these distinct modalities may offer new therapies for patients with SMARCA4 mutations.” #AACR #precisiononcology #Cancerresearch #SMARCA2

#Ariceum is pleased to announce that it will be presenting new #radioligand therapy data at the American Association for Cancer Research (#AACR) Annual Meeting 2024 in San Diego, California, from 5-10 April, 2024.   Join Anika Jäkel, Senior Director, Head of Translational Biology and Non-Clinical Pharmacology at #Ariceum on 9 April when she will present a poster demonstrating new findings on the discovery of novel macrocyclic peptide radioligands for tumor therapy by mRNA display in collaboration with research partner, UCB.   We look forward to sharing insights and connecting at #AACR2024. Learn more about the data in the press release in the comments below!   #lifesciences #biotech #radiopharmaceuticals #satoreotide #ATT001 #ATT002

At MitogenDx, we leverage cutting-edge technologies to advance diagnostic capabilities across diverse medical disciplines. Our offerings include: Simoa™ Based Assays: Achieve unparalleled sensitivity with femtogram-level biomarker detection across multiple sample types. Perfect for autoimmunity, inflammation, and oncology. Line Immunoassays (LIA): Differentiate antibody reactivity to multiple antigens on a single test strip, providing comprehensive antibody profiling with high specificity. Cell Based Assays: Utilize transfected cells to detect antibodies against specific antigens, enabling multiplexing and precise antibody identification. Luminex Assays: Employ microsphere-based technology for high-throughput, multiplex detection of analytes, ensuring rapid and accurate bioanalysis. Explore how these technologies are transforming diagnostics at MitogenDx. Learn more on this page: https://lnkd.in/dZREFm4T #MitogenDx #DiagnosticInnovation #HealthcareTechnology #PrecisionMedicine #Bioanalysis #ClinicalDiagnostics #MedicalResearch #Diagnostics

Why Test Drugs on Yourself? Your Tumor Avatars Are the Real Game Changers. 3D cell culture plates play a crucial role in precision oncology, offering a more accurate representation of the tumor microenvironment compared to traditional 2D cultures. R3CE® technology (Rapid, Reproducible, Rare Cell 3D Expansion) advances the field by enabling the expansion and growth of circulating tumor cells (CTCs). This cutting-edge platform improves the precision of drug selection and rechallenge strategies, supports ongoing tumor surveillance, and enables a broad range of downstream analyses. As a result, it facilitates the development of personalized treatment plans and enhances patient outcomes. By leveraging R3CE® technology, we can better understand tumor behavior, predict drug responses, and tailor therapies more effectively. Here we are delighted to share with you one of the applications, Onco-REAL™, a platform that transforms tumor insights into actionable therapies. I’ll let you explore its potential firsthand.

Register below for a free session to learn about SomaScan high-plex proteomics, and how we are delivering 11,000 protein insights from a single 55ul sample. Clinical grade proteomic data #precisionmedicine #somascan #proteomics #personalisedmedicine